WILATE

This brand name is authorized in Austria, Brazil, Canada, Ecuador, Estonia, Spain, Finland, Croatia, Ireland, Israel, Lithuania, Malta, Netherlands, New Zealand, Poland, Romania, Tunisia, United Kingdom, United States

Active ingredients

The drug WILATE contains a combination of these active pharmaceutical ingredients (APIs):

1 Human factor VIII UNII 839MOZ74GK - ANTIHEMOPHILIC FACTOR HUMAN

Activated factor VIII acts as a cofactor for activated factor IX, accelerating the conversion of factor X to activated factor X (factor Xa). Haemophilia A is a sex-linked hereditary disorder of blood coagulation due to decreased levels of factor VIII:C. By replacement therapy the plasma levels of factor VIII are increased, thereby enabling a temporary correction of the factor deficiency and correction of the bleeding tendencies. Read about Coagulation factor VIII

2 Von Willebrand factor UNII ZE22NE22F1 - VON WILLEBRAND FACTOR HUMAN

Administration of von Willebrand factor allows correction of the haemostatic abnormalities exhibited by patients who suffer from von Willebrand factor deficiency. Read about Von Willebrand factor

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
WILATE Powder and solvent for solution for injection	Health Products Regulatory Authority (IE)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
B02BD06	Von Willebrand factor and coagulation factor VIII in combination	B Blood and blood forming organs → B02 Antihemorrhagics → B02B Vitamin K and other hemostatics → B02BD Blood coagulation factors
Discover more medicines within B02BD06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 535315040002107, 535315040002207, 535317070002707, 535317070002807
Country: CA	Health Products and Food Branch	Identifier(s): 02286750, 02286769
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): 105-MBE-0617, 99-MBE-0517
Country: EE	Ravimiamet	Identifier(s): 1503593, 1503605
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 75625, 75648
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 407358, 417307
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 263058, 263068
Country: HR	Agencija za lijekove i medicinske proizvode	Identifier(s): HR-H-138328484, HR-H-758724968
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 7716, 7717
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1057510, 1057511, 1091499
Country: MT	Medicines Authority	Identifier(s): MA1219/01101, MA1219/01102
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 100404, 100412
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 12483, 12484
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100270469, 100270475
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W65361001, W65362001
Country: TN	Direction de la Pharmacie et du Médicament	Identifier(s): 10043041H, 10043042H
Country: US	FDA, National Drug Code	Identifier(s): 68982-182